Citi starts ArriVent stock with buy rating citing promising lung cancer drug
© Reuters. Tuesday, Citi initiated coverage on ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and a price target of $30.00. ...
Thursday, February 6, 2025
Tag: ArriVent
Plugin Install : Widget Tab Post needs JNews - View Counter to be installed
- Trending
- Comments
- Latest
Explore Israel's diverse narratives with The Israel Chronicle. Stay informed with unbiased reporting, insightful analysis, and comprehensive coverage of politics, culture, technology, and more. Discover the heartbeat of Israel through our trusted news platform.